A pilot study of nadolol for overt aggression in developmentally delayed individuals

Journal of the American Academy of Child and Adolescent Psychiatry
D F ConnorK E Fletcher

Abstract

The aim of this preliminary pilot study was to investigate the safety and efficacy of open-label nadolol as an adjunctive pharmacological treatment for aggression and/or inattention/overactivity in a developmentally delayed child, adolescent, and young adult population. Twelve subjects enrolled and completed (mean age 13.8 years, range 9 through 24) a 5-month, open, prospective protocol of nadolol (mean dose 109 mg, range 30 through 220 mg) with systematic baseline and outcome evaluations and weekly clinical assessment. All subjects were developmentally delayed and most were cognitively delayed. Ten subjects (83%) showed clinical improvement while receiving nadolol. Significant improvements were noted on observer-rated overt categorical aggression, severity of illness, and global impressions of improvement. No significant effects were found for inattention/overactivity. Nadolol was well tolerated, with few side effects. Overt categorical aggression presenting in developmentally delayed children, adolescents, and young adults may respond to nadolol treatment.

References

Apr 1, 1992·JAMA : the Journal of the American Medical Association·S C Yudofsky
Mar 1, 1991·Journal of the American Academy of Child and Adolescent Psychiatry·M G AmanS N Merry
Jan 1, 1985·European Journal of Clinical Pharmacology·W P Koella
Jan 1, 1986·The American Journal of Psychiatry·S C YudofskyD Williams
Jun 1, 1985·Journal of Abnormal Child Psychology·R Loeber, K B Schmaling
Jul 1, 1972·British Journal of Pharmacology·M H Lader, P J Tyrer
Aug 27, 1981·The New England Journal of Medicine·J Koch-Weser, W H Frishman
Feb 1, 1994·Journal of the American Academy of Child and Adolescent Psychiatry·D W Gillette, L P Tannery
Jul 1, 1996·Journal of Child Psychology and Psychiatry, and Allied Disciplines·J K BuitelaarM Kuiper
Sep 20, 1996·Annals of the New York Academy of Sciences·D F Connor, R J Steingard
Feb 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·D F ConnorR H Melloni
Jan 1, 1996·The Journal of Neuropsychiatry and Clinical Neurosciences·V KafantarisM Campbell
Jul 1, 1993·Journal of Child and Adolescent Psychopharmacology·D F Connor
Jan 1, 1991·Journal of Child and Adolescent Psychopharmacology·L E Arnold, M G Aman

❮ Previous
Next ❯

Citations

Jan 5, 2001·European Child & Adolescent Psychiatry·J Biederman, T Spencer
Mar 9, 2007·Journal of Child and Adolescent Psychopharmacology·Rosa-Elena UlloaAlonso Fernández-Guasti
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Sarah B SchurPeter S Jensen
May 25, 2011·Southern Medical Journal·Manu AroraVinod Kumar Sinha
Mar 7, 2012·Journal of Immunotoxicology·David BasketterBeth Concoby
Oct 16, 2015·Acta Paediatrica·Pieta R WinterSwee T Tan
May 28, 2004·Pediatric Annals·Steven Ruths, Hans Steiner
Mar 11, 2006·Child and Adolescent Psychiatric Clinics of North America·Marie V SollerHans Steiner
Jan 7, 2003·Child and Adolescent Psychiatric Clinics of North America·Kenneth E Towbin
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Scott M Myers
Aug 30, 2001·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·L Baving, M H Schmidt
Jan 19, 2016·Current Opinion in Psychiatry·Na Young Ji, Robert L Findling
Apr 11, 2003·Journal of Attention Disorders·T Spencer, J Biederman
Jan 9, 2021·Harvard Review of Psychiatry·David S Im
Apr 29, 2008·Journal of Child and Adolescent Psychopharmacology·Daniel F ConnorMary Jeffers-Terry
Oct 31, 2007·Pediatrics·Scott M MyersUNKNOWN American Academy of Pediatrics Council on Children With Disabilities

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.